Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Savitt

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of the Neurological Sciences|May 20, 2019
Clinical phenotype in carriers of intermediate alleles in the huntingtin geneDaniel Savitt, Joseph Jankovic
Journal of the Neurological Sciences|March 7, 2018
Tardive syndromesDaniel Savitt, Joseph Jankovic
Neurology. Clinical Practice|March 13, 2019
Levodopa-induced dyskinesias in mitochondrial membrane protein-associated neurodegenerationDaniel Savitt, Joseph Jankovic
Drugs|April 15, 2019
Targeting α-Synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying TherapeuticsDaniel Savitt, Joseph Jankovic
Parkinsonism & Related Disorders|March 25, 2023
Interactive mobile application for Parkinson's disease deep brain stimulation (MAP DBS): An open-label, multicenter, randomized, controlled clinical trialGordon Duffley, Aniko Szabo, Barbara J Lutz, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of the Neurological Sciences|May 20, 2019
Clinical phenotype in carriers of intermediate alleles in the huntingtin geneDaniel Savitt, Joseph Jankovic
Journal of the Neurological Sciences|March 7, 2018
Tardive syndromesDaniel Savitt, Joseph Jankovic
Neurology. Clinical Practice|March 13, 2019
Levodopa-induced dyskinesias in mitochondrial membrane protein-associated neurodegenerationDaniel Savitt, Joseph Jankovic
Drugs|April 15, 2019
Targeting α-Synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying TherapeuticsDaniel Savitt, Joseph Jankovic
Parkinsonism & Related Disorders|March 25, 2023
Interactive mobile application for Parkinson's disease deep brain stimulation (MAP DBS): An open-label, multicenter, randomized, controlled clinical trialGordon Duffley, Aniko Szabo, Barbara J Lutz, et al.
Pageof 1